Özet:

The purpose. This study aimed at analyzing survival, treatment side effects and prognostic factors affecting survival of brain tumor patients treated with adjuvant radiotherapy or chemoradiotherapy. The Method. In the study, the data of 76 patients with brain tumors followed by the Research and Applied Hospital of the Republic University Medical Faculty were retrospective examined. The findings. Fifty (67%) men and 25 (33%) women included a total of 76 patients in the study. Histopathologically: 18 (24%) had low-degree glial tumor, 17 (22%) had high-degree glial tumor, 33 (4%) had multiform glioblastoma, 4 (5%) had hypofysic adenoma and 4 (5%) had medullablastoma. The average follow-up period was 16 months (1-199 months). Two-year overall survival and two-year non-sick survival: 83% and 83% of low-degree glial tumors, 46% and 40% of high-degree glial tumors, 28% and 24% of glioblastoma multiforme patients were identified. In single variable analysis, the overall survival of patients was affected by histopathology ( < 0,001), age (≤50 and > 50, p < 0,001), grade (p:0,003), Ki-67 value (≤10 and > 10, p: 0,016), performance status of the Eastern Cooperative Oncology Group (p:0,006) and surgical (compared with total resection with biopsy, p:0,017). In the multi-variable analysis, grade (p: 0.013), age (p:0,025) and performance status of the Eastern Cooperative Oncology Group (p < 0.001) were prognostic factors that independently influenced survival. If the acute side effects were observed, 51 (67%) patients had headaches, 32 (42%) patients had discomfort. Radiotherapy necrosis was also diagnosed in 3 (5%) patients. The result. In this study, glioblastoma multiforme and high-degree glial tumors showed similar results with literature, except for general and non-sick survival of low-degree glial tumors. The important prognostic factors for this group of patients were determined as grade, age and performance status of the Eastern Cooperative Oncology Group.

Anahtar Kelimeler: